| abstract |
The present invention relates to a novel biomarker for predicting sensitivity to a MET inhibitor and use thereof. More specifically, a biomarker for predicting sensitivity to a MET inhibitor including IGSF1 (Immunoglobulin Superfamily member 1, NM_001555.2) gene; and the expression level of the biomarker gene or the expression level of the protein A composition for predicting sensitivity to a MET inhibitor comprising a preparation to be measured; and dysregulation of a MET signaling pathway comprising as an active ingredient an inhibitor that suppresses the expression of the biomarker gene or the expression or activity of the protein of the gene And a method for predicting sensitivity to a MET inhibitor; a pharmaceutical composition for treating a disease associated with the disease; a kit for predicting sensitivity to a MET inhibitor comprising the composition; According to the present invention, since the present invention has an excellent effect of predicting sensitivity to MET inhibitors in gastric cancer or lung cancer, the present invention can be usefully used for the treatment of gastric cancer or lung cancer. [Selection] Figure 5a |